Yang Li

The farnesoid X receptor agonist EDP‐305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction

P. Caravan, K. Tanabe, B. Fuchs, 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

P. An, Shucha Zhang, Y. Popov, 2020, Liver international : official journal of the International Association for the Study of the Liver.

Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis

Y. Or, R. Shen, M. Chau, 2019, International Journal of Gastroenterology.

Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP‐305, a novel farnesoid X receptor agonist

C. Farrar, P. Caravan, K. Tanabe, 2018, Hepatology communications.